All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 4th European CAR T-Cell Meeting, the Multiple Myeloma Hub was pleased to speak to Arnon Nagler, Sheba Medical Center, Tel Aviv, IL. We asked, how do CAR T-cell recipients respond to COVID-19 vaccination
How do CAR T-cell recipients respond to COVID-19 vaccination?
In this video, Nagler discusses chimeric antigen receptor (CAR) T-cell therapy (CAR-T). He also highlights the challenges that COVID-19 has caused to CAR-T and the implications for patients with; Non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Access and future prospects of advanced immunotherapies for multiple myeloma in Europe
During the 4th European CAR T-cell Meeting, the Multiple Myeloma Hub was pleased to speak with Michel Delforge, UZ Leuven, Leuven, BE. We asked, What are the...
The impact of COVID-19 on the management of patients with multiple myeloma
An article, by Elena Zamagni, Paola Tacchetti, and Michele Cavo, discussing the impact of COVID-19 on the management of patients with multiple myeloma. SARS-CoV-2.
Subscribe to get the best content related to multiple myeloma delivered to your inbox